Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines.

Full text not archived in this repository.

Please see our End User Agreement.

It is advisable to refer to the publisher's version if you intend to cite from this work. See Guidance on citing.

Add to AnyAdd to TwitterAdd to FacebookAdd to LinkedinAdd to PinterestAdd to Email

Greco, F. and Vicent, M. (2009) Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines. Advanced Drug Delivery Reviews, 61 (13). pp. 1203-1213. ISSN 0169-409X doi: 10.1016/j.addr.2009.05.006

Abstract/Summary

The discovery of new molecular targets and the subsequent development of novel anticancer agents are opening new possibilities for drug combination therapy as anticancer treatment. Polymer-drug conjugates are well established for the delivery of a single therapeutic agent, but only in very recent years their use has been extended to the delivery of multi-agent therapy. These early studies revealed the therapeutic potential of this application but raised new challenges (namely, drug loading and drugs ratio, characterisation, and development of suitable carriers) that need to be addressed for a successful optimisation of the system towards clinical applications.

Altmetric Badge

Item Type Article
URI https://reading-clone.eprints-hosting.org/id/eprint/4406
Identification Number/DOI 10.1016/j.addr.2009.05.006
Refereed Yes
Divisions Life Sciences > School of Chemistry, Food and Pharmacy > School of Pharmacy > Pharmaceutics Research Group
Uncontrolled Keywords Polymer-conjugate; Polymer therapeutics; Nanomedicine; Targeted drug delivery; Combination therapy; Cancer
Publisher Elsevier Science BV
Download/View statistics View download statistics for this item

University Staff: Request a correction | Centaur Editors: Update this record

Search Google Scholar